A short course of immunotherapy given before surgery eliminated detectable colon cancer in a majority of patients whose ...

LUND, SE / ACCESS Newswire / July 2, 2026 / Alligator Bioscience (STO:ATORX)First patient dosed in an investigator-initiated trial evaluating intratumoral mitazalimab, with or without intratumoral ...

Genomic stratification (OPTIMA/Prosigna PAM50) supported endocrine-alone management for ER+/HER2– patients with low recurrence-risk scores, reframing chemotherapy benefit as largely ...

Durable ZUMA-2 follow-up converted brexu-cel to traditional approval in r/r MCL, while sonrotoclax gained accelerated approval post-BTK inhibitor based on 52% ORR. Breast-cancer decisions expanded ...

1 Department of General Surgery, Pancreatic Disease Centre, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China 2 Ruijin-Hainan Hospital Shanghai Jiao Tong ...

Brain metastases are a major challenge in HER2-positive metastatic breast cancer; epidemiologic series suggest that roughly 30%–50% of patients eventually develop brain involvement, which is ...

Objectives To assess the outcomes of patients undergoing open abdominal surgery at a National Referral Hospital in Tanzania. Design A prospective, observational, single-arm cohort study. Setting Dar ...

Peripheral retinal lesions occurred in 54.4% of highly myopic pediatric eyes, were bilateral in 64.2%, and increased in prevalence and multiplicity with age and more negative spherical equivalent.

Cardiac excitation–contraction coupling (ECC) is the orchestrated process of initial myocyte electrical excitation, which leads to calcium entry, intracellular trafficking, and subsequent sarcomere ...

If the US FDA approves it, aglatimagene immunotherapy may become the first new therapy for men with localized prostate cancer in the past 2 decades.

As you all know, Alnylam is pioneering an entirely new class of medicines to treat human disease. This generational technology leverages the mechanism of RNA interference, a natural process of gene ...

Merck MRK announced that the European Commission has approved its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), and ...